According to the offshore protein announcement, the cumulative closing price increase deviation value of the company's stock exceeded 30% for 3 consecutive trading days on September 28, September 29, and September 30, 2026, and the cumulative closing price deviation value reached 100% for 10 consecutive trading days from September 16 to September 30, which is a serious abnormal fluctuation in stock trading. After self-inspection and consultation with the controlling shareholders and actual controllers, there was no significant information that should be disclosed but not disclosed. The directors, supervisors, controlling shareholders, and actual controllers did not trade the company's shares during the period of abnormal fluctuations. The company had a net loss of 29.204 million yuan in the first half of 2026, an increase of 4.989 million yuan; as of September 30, 2026, the closing market sales rate was 73.37, which was significantly higher than that of comparable companies in the same industry. AI-related businesses accounted for less than 2% of revenue, and RNA vaccine-related products accounted for relatively low revenue, reminding investors to pay attention to investment risks.

According to the offshore protein announcement, the cumulative closing price increase deviation value of the company's stock exceeded 30% for 3 consecutive trading days on September 28, September 29, and September 30, 2026, and the cumulative closing price deviation value reached 100% for 10 consecutive trading days from September 16 to September 30, which is a serious abnormal fluctuation in stock trading. After self-inspection and consultation with the controlling shareholders and actual controllers, there was no significant information that should be disclosed but not disclosed. The directors, supervisors, controlling shareholders, and actual controllers did not trade the company's shares during the period of abnormal fluctuations. The company had a net loss of 29.204 million yuan in the first half of 2026, an increase of 4.989 million yuan; as of September 30, 2026, the closing market sales rate was 73.37, which was significantly higher than that of comparable companies in the same industry. AI-related businesses accounted for less than 2% of revenue, and RNA vaccine-related products accounted for relatively low revenue, reminding investors to pay attention to investment risks.